UBS
http://www.ubs.com/UBS provides a range of financial services, including advisory services, underwriting, financing, market making, asset management, brokerage and retail banking on a global level. The Company consists of four divisions: Wealth Management, Asset Management, Investment Banking & Security and Swiss Retail & Corporate Banking. Wealth Management offers high net worth customers advice and investment services, Asset Management offers management solutions for most types of asset class to a range of clients, Investment Banking & Security provides securities, products and research in various areas equities and Swiss Retail & Corporate Banking offers banking and securities services for Swiss clients.
-
Trading Radar for 04/30: Pfizer (PFE), Cummins (CMI), McGraw-Hill (MHP), DreamWorks (DWA), Sirius (SIRI) Report
-
Zoetis (ZTS) Closes 86.1M IPO; Pfizer (PFE) Remains 80% Owner
-
Pfizer's Zoetis (ZTS) Sees IPO Price of $22 - $25/Share
-
Notable Analyst Rating Changes 11/30: (STJ) (ULTA) (TOT) Upgraded; (YUM) (TIF) (NTLS) Downgraded
-
Market Wrap: H-P's $8.8B Oversight; New Housing Starts at 4-Year High; UBS Trader Gets Comeuppance; SAC Capital Under Fire
-
Notable Mergers and Acquisitions of the Day 10/22: (BP) (HK) (LDK) (PFE)
-
Pre-Open Movers 8/7: (USHS) (BSFT) (FOSL) Higher; (WMS) (LEAP) (NIHD) Lower (more...)
-
Top 10 News Items 07/30 - 08/03: More Jobs Added in July, Unemployment Rises; Knight Capital's Expensive Folly; FOMC Likes Rates, Remains on Watch
-
Trading Radar for 07/31: US Steel (X), Coach (COH), Electronic Arts (EA), UBS AG (UBS), Goodyear(GT) Report
-
UBS Q2 Preview on U.S. Pharmaceuticals: Safe Havens in Generic, Specialty and Large-Cap
-
UBS on U.S. Pharma - Large Cap and Specialty: Q1 Preview - Off to a Good Start
-
UBS on U.S. Pharma – Large Cap and Specialty: 4Q11 Preview: Things Still Look Interesting
-
UBS Maintains a 'Neutral' on Greenlight Capital (GLRE); Lowering Estimates and Price Target
-
Morning Movers 06/28: (YOKU) (ICGN) (LNKD) Higher; (AMBO) (ABH) Lower
-
Notable 52-Week Highs and Lows of the Day 06/27: (ICGN) (CROX) (SAPE) High; (PTIE) (HOGS) (DWA) Low
-
UBS Maintains a 'Buy' on Mylan (MYL); Lipitor/Caduet Fuels Upward Momentum
-
UBS Maintains a 'Buy' on Protalix (PLX); Capture Brazilian Gaucher Market
-
UBS Downgrades King Pharma (KG) to Neutral; Goodbye King
-
Genomic Health (GHDX) To Present Data from First Collaboration with Pfizer (PFE) Oncology
-
Public Health Care Coming, But Stocks Trade Higher
-
Top 10 News Items 2/1-2/5: 9.7% Unemployment Rate Surprises the Market, Dow Breaks 10,000, But Recovers, Troubles at Toyota Continue
-
Notable Analyst Rating Changes 12/16: CNQ, SCHW, RCL, CCL, NLY, GLW, BFS, ADBE Upgraded; AYE, FE, EIX, STLD Downgraded
-
UBS Modestly Positive On US Large-Cap Pharma (MRK, PFE, BMY, LLY)
-
Morning Movers 5/18: KONA, AHR, IDMI, LGTY, IBN, HEB Higher; SPIR, COIN, BIDZ, AYE Lower
-
David Moenning's Daily State of the Markets: 4/28
-
Trading Radar for 4/28: Bristol-Myers Squibb (BMY), Pfizer (PFE), BP (BP), Sun Micro (JAVA), Deutsche Bank (DB), E*TRADE (ETFC), Level 3 (LVLT) Report; Consumer Confidence Due
-
Notable Analyst Rating Changes 3/5: BIDU, T, ADBE, SIGM Upgraded; CXR, RIO, GPS Downgraded
-
David Moenning's Daily State of the Markets: 2/9
-
Notable Analyst Rating Changes 2/9: WYE, PFE, ADBE, CHK, GLW, BIG Upgraded; LEN, PAS, CVX, DOW Downgraded
-
UBS Upgrades Pfizer (PFE) to Buy
-
Reports Sanofi-Aventis (SNY) On The Prowl For Mergers
-
Notable Analyst Rating Changes 11/14: CLX, LDK, ALO, URBN Upgraded; GSK, EMR, LHO, UDR Downgraded
-
Notable Analyst Rating Changes 11/07: ANF, TWTC, CECEO Upgraded; TM, DLB, SI Downgraded
-
Morning Movers 10/21: Texas Instruments (TXN) Lower on Results/Guidance, 3M (MMM) Higher
-
David Moenning's Daily State of the Markets: 10/20
-
Notable Analyst Rating Changes 10/20: KFT, RIG, BBY, PFE, YGE Upgraded; DE, INTC, MET, POZN Downgraded
-
Pre-Open Movers 9/3: Medivation (MDVN) Surges On Pfizer Deal; Corning (GLW) Sinks on Warning
-
David Moenning's Daily State of the Markets: 7/23
-
Notable Analyst Rating Changes 6/5: NVDA, SGP, UAUA Upgraded; PFE, MOT, CAT, HAYN Downgraded
-
David Moenning's Daily State of the Markets: 4/17
-
Pfizer (PFE) and AVANT (AVAN) Enter into Licensing and Development Agreement
-
Pfizer (PFE) Announces Additional Benefit From Lipitor in Recent Study
-
Shire plc (SHPGY) Higher On AstraZeneca Takeover Rumors
-
Notable Analyst Rating Changes 2/29: PFE, DELL, DECK Upgraded; MF, JTX, TTWO Downgraded
-
David Moenning's Daily State of the Markets: 1/23
